icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TEZSPIRE (Tézépélumab).
See also
Décision d'accès précoce
22/12/2022
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
sWFjpnGTAgGrZfXj